Hepatobiliary malignancies have a stealthy onset and are often diagnosed at advanced stages, making surgical intervention impossible and resulting in a very dismal overall prognosis. However, with the gradual promotion and application of neoadjuvant therapy concepts in the management of solid malignancies, as well as the rapid progress of emerging treatment methods led by immunotherapy, more and more patients with advanced, unresectable hepatobiliary tumors can now have the opportunity for translational resection through neoadjuvant therapy, thus significantly extending their survival time. Therefore, new approaches to neoadjuvant therapy and translational resection in hepatobiliary malignancies are emerging research hotspots with significant clinical translational value.
The goal of this Research Topic is to provide a forum to advance research on the latest developments in neoadjuvant therapies for hepatobiliary malignancies, as well as to discuss the clinical applications of translational liver resection and its current controversies regarding the selection of surgical timing, determining the optimal resection plan, and whether to continue with adjuvant therapy after surgery. The aim is to establish standardized and effective neoadjuvant therapy approaches, as well as precise evaluation processes for translational resection following neoadjuvant therapies. By bringing together leading experts in the field, this special issue will provide a comprehensive overview of the current state of neoadjuvant therapy and translational resection for hepatobiliary malignancies and will promote further research and development in this important area.
We welcome submissions of Original Research and Review articles. A Research Topic on “New Approaches to Neoadjuvant Therapy and Translational Resection in Hepatobiliary Malignancies” had the bullet points as below:
(1) Advances in neoadjuvant therapy approaches for hepatobiliary malignancies;
(2) The application of PD-1/PD-L1 inhibitors in neoadjuvant therapy for hepatobiliary tumors;
(3) Methods and timing for evaluating the efficacy of neoadjuvant therapy;
(4) Screening and evaluation of patients for translational resection;
(5) Technical challenges and innovations in translational resection;
(6) Perioperative management of patients undergoing translational resection;
(7) Development and research progress of postoperative adjuvant therapy regimens.
Please NOTE: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of the scope for this section and will not be accepted as part of this Research Topic.
Hepatobiliary malignancies have a stealthy onset and are often diagnosed at advanced stages, making surgical intervention impossible and resulting in a very dismal overall prognosis. However, with the gradual promotion and application of neoadjuvant therapy concepts in the management of solid malignancies, as well as the rapid progress of emerging treatment methods led by immunotherapy, more and more patients with advanced, unresectable hepatobiliary tumors can now have the opportunity for translational resection through neoadjuvant therapy, thus significantly extending their survival time. Therefore, new approaches to neoadjuvant therapy and translational resection in hepatobiliary malignancies are emerging research hotspots with significant clinical translational value.
The goal of this Research Topic is to provide a forum to advance research on the latest developments in neoadjuvant therapies for hepatobiliary malignancies, as well as to discuss the clinical applications of translational liver resection and its current controversies regarding the selection of surgical timing, determining the optimal resection plan, and whether to continue with adjuvant therapy after surgery. The aim is to establish standardized and effective neoadjuvant therapy approaches, as well as precise evaluation processes for translational resection following neoadjuvant therapies. By bringing together leading experts in the field, this special issue will provide a comprehensive overview of the current state of neoadjuvant therapy and translational resection for hepatobiliary malignancies and will promote further research and development in this important area.
We welcome submissions of Original Research and Review articles. A Research Topic on “New Approaches to Neoadjuvant Therapy and Translational Resection in Hepatobiliary Malignancies” had the bullet points as below:
(1) Advances in neoadjuvant therapy approaches for hepatobiliary malignancies;
(2) The application of PD-1/PD-L1 inhibitors in neoadjuvant therapy for hepatobiliary tumors;
(3) Methods and timing for evaluating the efficacy of neoadjuvant therapy;
(4) Screening and evaluation of patients for translational resection;
(5) Technical challenges and innovations in translational resection;
(6) Perioperative management of patients undergoing translational resection;
(7) Development and research progress of postoperative adjuvant therapy regimens.
Please NOTE: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of the scope for this section and will not be accepted as part of this Research Topic.